[go: up one dir, main page]

WO2003035021A1 - Composition topique potentialisee - Google Patents

Composition topique potentialisee Download PDF

Info

Publication number
WO2003035021A1
WO2003035021A1 PCT/SE2002/001908 SE0201908W WO03035021A1 WO 2003035021 A1 WO2003035021 A1 WO 2003035021A1 SE 0201908 W SE0201908 W SE 0201908W WO 03035021 A1 WO03035021 A1 WO 03035021A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
weight
diol
skin
pentane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/SE2002/001908
Other languages
English (en)
Inventor
Jan Faergemann
Thomas Hedner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to DK02778165.7T priority Critical patent/DK1446093T3/en
Priority to US10/491,992 priority patent/US8642053B2/en
Priority to EP02778165.7A priority patent/EP1446093B1/fr
Priority to NZ533087A priority patent/NZ533087A/en
Priority to CA2469474A priority patent/CA2469474C/fr
Priority to AU2002339819A priority patent/AU2002339819B2/en
Priority to ES02778165.7T priority patent/ES2628707T3/es
Publication of WO2003035021A1 publication Critical patent/WO2003035021A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/345—Alcohols containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0208—Tissues; Wipes; Patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
    • A61Q1/02—Preparations containing skin colorants, e.g. pigments
    • A61Q1/04—Preparations containing skin colorants, e.g. pigments for lips
    • A61Q1/06—Lipsticks
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/007—Preparations for dry skin

Definitions

  • the present invention relates to potentiated topical compositions, that is, topical compositions for cosmetic use or comprising a pharmacologically active agent, the cosmetic or pharmacological effect of which is potentiated by a carrier constituent which has little pharmacological effect per se .
  • compositions for topical administration usually are slow and often too slow to be of practical value.
  • the methods known in the art to enhance penetration frequently use adjuvants or mixtures of adjuvants to enhance absorption. However many of the more effective adjuvants irritate the skin or are toxic or smelly or stain the clothes they come into contact with.
  • Pentane-1, 5-diol is known to possess antiviral, antifungal and antibacterial activity, in particular antiviral activity against herpes simples virus (U.S. patent no. 5,369,129).
  • Pentane-1, 5-diol has been used as an adjuvant component in the transdermal administration of the antihypertensive drug prazosine (WO 93/03697) in combination with a sulfhydryl-containing compound and a fatty ester.
  • U.S. patent no. 5,550,145 discloses an antimicrobial composition comprising a monoglyceride and 5% by weight of pentane-1, 5-diol .
  • U.S. patent no. 4,241,084 discloses an antibacterial and antifungal composition comprising a sulfonamide and an alkylene glycol containing from 5 to 8 carbon atoms and an alkylene glycol ester.
  • WO 96/11572 discloses a antimicrobial composition comprising carboxylic acids of up to ten carbon atoms or their salts and C 3 -C ⁇ 0 -diols.
  • WO 93/20812 discloses an antimicrobial composition comprising a) monoglyceride of lauric acid, a monoglyceride of mono- myristic acid or their mixtures, an antibacterial substance and a diol with 3-6 carbon atoms.
  • EP 0 884 045 Al discloses a self-tanning skin composition comprising a self-tanning skin coloring agent, a polyethoxyalcohol, a polyol and, optionally, a pentanediol.
  • WO 98/27960 discloses a viscous hydrogel composition for topical administration comprising a microbially active nitro- imidazole drug, pentylene glycol and a hydroxyalkyl cellulose gelling agent and water, buffered to a physiologically acceptable pH.
  • U.S. patent no. 5,879,690 discloses a composition for treatment of sagging subcutaneous muscle comprising an agent exhibiting or producing catecholamine activity and a carrier comprising skin penetration enhancer such as pentanediol.
  • GB 2 280 111 A discloses clear gel antiperspirant compositions comprising an antiperspirant, pentanediol, a co-solvent of polyethylene glycol, water and/or glycerin, a buffering agent and a gelling agent.
  • Propylene glycol is a hygroscopic liquid widely used as a carrier in topical preparations. It is very hygroscopic and considered generally non-toxic (exception: ototoxicity) in contrast to ethylene glycol and hexylene- 1,6-glycol (for a review, see: Goldsmith, L A. Propyl ene glycol . Int J Dermat 1978; 17:703-705).
  • compositions for skin care which has improved properties in comparison to compositions known in the art, in particular compositions containing propane-1, 2-diol as a carrier.
  • the present invention is based on the insight that propylene glycol can be advantageously substituted in many cosmetic and pharmaceutical compositions by pentane- 1, 5-diol.
  • a topical composition for skin care or administration of a pharmacologically active agent comprising from 5% by weight to 70% by weight of pentane-1, 5-diol and a cosmetically or pharmaceutically acceptable carrier, with the proviso that the composition does not comprise polysiloxane, volatile siloxane, phosphatidylcholine, creatine, carnitine, panthenol, pyruvic acid, mono- glyceride of lauric acid, monoglyceride of myristic acid. It is preferred for the composition to comprise from 15 % by weight to 40% by weight of pentane-1, 5-diol, more preferred from 20-35% of pentane-1, 5-diol .
  • the cosmetically or pharmaceutically acceptable carrier comprises less than 20% or 10% by weight of propane-1, 2- diol, glycerol or a combination thereof, more preferred less than 5 % by weight of propane-1, 2-diol, glycerol or a combination thereof, most preferred less than 1 % by weight of propane-1, 2-diol, glycerol or a combination thereof.
  • the cosmetic or pharmaceutical composition preferably comprises from 0.1 to 30% by weight of water.
  • the cosmetic or pharmaceutical composition of the invention comprises a tonicity adjusting agent; from 0.1% by weight to 20 % by weight of a moisturizing agent selected from carbamide, NaCl, lactic acid, and their combinations; from 0.1 to 30 % by weight of polyethylene glycol; a UV-absorbing agent; a colorant selected from titanium dioxide, calcium carbonate, and zinc oxide; a fragrant agent.
  • cosmetic or pharmaceutical composition is in the form of a cream, a liquid, a lotion, an ointment, a paste, a gel, a shampoo, a spray, a lipstick.
  • the cosmetic or pharmaceutical composition is carried by a patch impregnated with it.
  • the cosmetic of pharmaceutical composition comprises an anionic emulsifying wax, such as Cetylanum.
  • the pharmaceutical composition comprises a pharmacologically active agent selected from steroids, antimycotic agents, agents for treating diseases of the thyroidea, antibiotics, antiviral agents, antihistamins, antiseptics, agents for the treatment of acne, agents for the treatment of warts, NSAIDs, C0X2 selective agents, local anesthetics, agents for the treatment of psoriasis and eczema, cytostatics, polypeptides, TNF- blockers, as well as other agents used in the treatment of diseases affecting the skin.
  • Salicylic acid is a preferred pharmacologically agent.
  • the cosmetic or pharmaceutical composition is provided in a sealed container.
  • a cosmetic or medical patch provided with the composition of the invention; the patch is optionally enclosed in a sealed plastic envelope.
  • a method of topically administering a pharmaceutical agent comprising forming a solution, emulsion, suspension, ointment or cream of a pharmacologically effective amount of said agent in a carrier comprising from 5% to 70% by weight of pentane- 1, 5-diol, followed by applying said solution, emulsion, suspension, ointment or cream to a selected site of the skin of a person to be treated for a condition or disease against which said pharmaceutical agent is effective.
  • the administration comprises providing said composition on a patch or other suitable device for holding it against the selected skin site.
  • a method of treating or preventing a dry skin condition comprising (i) providing a pharmaceutical composition in form of a solution, emulsion, suspension, ointment or cream, which comprises from 5% to 70% by weight of pentane-1, 5-diol, and (ii) applying the solution, emulsion, suspension, ointment or cream to a selected site of the skin of a person to be treated.
  • the method comprises providing the composition on a patch (including absorbed by a patch) or other suitable device capable of being applied to the selected site of the skin, preferably for a period of time exceeding 6 hours and even 24 hours.
  • the pharmaceutical composition used in the method not to comprise polysiloxane, volatile siloxane, phosphatidylcholine, creatine, carnitine, panthenol, pyruvic acid, monoglyceride of lauric acid, monoglyceride of myristic acid.
  • a method of preserving the skin of a person in a humid state comprising (i) providing a cosmetic composition in form of a solution, emulsion, suspension, ointment or cream, which comprises from 5% to 70% by weight of pentane-1, 5-diol, and (ii) applying the solution, emulsion, suspension, ointment or cream to the skin to be preserved in a humid state.
  • the cosmetic composition used in the method not to comprise polysiloxane, volatile siloxane, phosphatidyl-choline, creatine, carnitine, panthenol, pyruvic acid, monoglyceride of lauric acid, monoglyceride of myristic acid.
  • pentane-1, 5-diol for the manufacture of a medicament for preventing and/or treating a dry skin condition and for the manufacture of a cosmetic capable of preserving skin in a humid condition.
  • the composition of the present invention may also be used for storage and transport of organs and tissue, in particular skin tissue.
  • composition of the invention is also useful for skin protection against dehydration and in the treatment and prevention of dry skin, including the prevention of dermatitis.
  • Cream A (prior art) : 0.1 % by weight of powderous tiratricol was blended with 99.9 % by weight of Essex cream containing 10% by weight of pentane-1, 5-diol .
  • Cream B (cream according to the invention) : 0.1 % by weight of powderous tiratricol was blended with a mixture of 10 % by weight of propane-1, 2-diol and 89.9 % by weight of Essex® cream base (Schering Plough) .
  • Creams A and B were compared in respect of release of tiritricol in a multilayer membrane system for determining percutaneous absorption (Bronaught, R L and Stewart, R L, Methods for in vi tro percutaneous absorption studies III. Hydrophobic compounds . J Pharm Soc 1984; 73:1255-1258); Bronaught R L et al . , Determina tion of Percutaneous Absorption by In Vi tro Techniques) . Bronaught R L et al., Methods for in vi tro percutaneous absorption studies II. Comparison of human and animal skin . Toxicol Appl Pharmacol 1982; 62:481-488; Bronaught R L et al . , Methods for in vi tro percutaneous absorption studies VI. Preparation of the barrier layer. J Pharm Sci 1986, 76:487-491). A Skin Penetration System 3-6 item # LG-1084- CS (3.0 ml cells) manufactured by Laboratory Glass
  • EXAMPLE 2 In vitro water binding capacity of pentane-1,5- diol, propane-1,2-diol, and urea.
  • the water binding capacity of pentane-1, 5-diol, propane-1, 2-diol, and urea was investigated in vi tro using pieces of human stratum corneum from a volunteer (for the method, see: Swanbeck, G. A new treatment of ichthyosis and other hyperkeratotic condi tions . Acta derm.-venerol. 48:123-127, 1968).
  • the specimens were cut into pieces of about 3x3x0.5 mm and used as such, The specimens were immersed for 12 hours in distilled water, aqueous pentane-1, 5-diol (10% by weight), aqueous propane-1, 2-diol (10% by weight) or aqueous urea (10% by weight) . The specimens then were blotted on filter paper and placed in a moisture over a saturated sodium tartrate solution providing a relative humidity of about 85% at 22 °C. After 6 hrs the specimens were removed and weighed. Their water content at 6 h was obtained by subtracting the weight of the specimens dried for 24 hrs in a dry atmosphere at room temperature. The results are shown in Table 2.
  • the water binding capacity after 6 hrs was 9% by weight for pentane-1, 5-diol, 7% by weight for propane-1, 2- diol, and 17% by weight for urea.
  • An aqueous solution containing 20% of pentane-1, 5-diol increased the water binding capacity to 13% by weight (water content 24%) .
  • EXAMPLE 3 Acute toxicity of pentane-1 , 5-diol .
  • Pentane-1, 5-diol was administered to the eye (conjunctiva) of five albino rabbits. Only very mild irritation (score 2 on a 1-10 scale) was observed.
  • a medical cotton patch (5 x 5 x ca. 1 cm) backed by perforated polyethylene on one side was provided with about 3 g of composition A on its front side and positioned against the skin of a volunteer (upper left arm) for a period of 24 hrs. Upon removal the skin seemed free from irritation.
  • Dry skin is a problem in patients with atopic dermatitis, psoriasis, ichtyosis and many other dermatological disorders.
  • Urea or a combination of urea and sodium chloride in various formulations creams, lotions, etc.
  • One important problem with these formulations is itching and burning when they are applied on eczematous skin.
  • the aim of the present experiments was to evaluate the water binding capacity of pentane-1, 5-diol in vi tro, and to compare it with that of urea.
  • Pieces of stratum corneum from the sole of 7 healthy volunteers were used. They were cut into pieces of about 3 x 3 x 0.5 mm and used as such.
  • the specimens were immersed for 12 hours in distilled water, aqueous pentane- 1, 5-diol (20 % by weight), and aqueous urea (10 % by weight) . Thereafter the specimens were blotted on filter paper and placed in a moist chamber with a saturated sodium tartrate salt solution giving a relative humidity, in the chamber, of about 85 %.
  • the specimens were removed after 24 hours for weighing.
  • the water content (WC) of the specimens at 24 hours was obtained by subtracting the weight of the specimen after drying for 24 hours in a dry atmosphere at room temperature.
  • the results are listed in Table 3.
  • the water binding capacity was estimated by subtracting the WC for stratum corneum incubated with distilled water for 24 hours from the WC for the stratum corneum pieces incubated with the test substances for 24 hours.
  • the water binding capacity after 24 hours was 23 % (mean) for pentane-1, 5- diol and 16 % (mean) for urea.
  • the water binding composition of the invention containing 20 % by weight of pentane-1, 5-diol, a better water retaining effect was obtained than with an aqueous composition containing 10 % by weight of urea. While the latter composition does give rise to itching when applied to eczematous skin, this negative effect is not encountered with the composition according to the invention.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)

Abstract

Composition topique pour les soins de la peau ou pour l'administration d'un principe actif sur le plan pharmacologique, sous forme d'une lotion, d'une crème ou similaire, qui contient 5 à 70 % en poids de pentane-1,5-diol et un excipient acceptable sur le plan cosmétique ou pharmaceutique, à condition que ladite composition ne contienne pas de polysiloxane, de siloxane volatil, de phosphatidylcholine, de créatine, de carnitine, de panthénol, d'acide pyruvique, de monoglycéride d'acide laurique et de monoglycéride d'acide myristique. Des procédés correspondants d'administration, un timbre pour maintenir ladite composition contre la peau et des procédés permettant de prévenir ou de traiter la peau sèche et de maintenir la peau hydratée sont également décrits.
PCT/SE2002/001908 2001-10-21 2002-10-18 Composition topique potentialisee Ceased WO2003035021A1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
DK02778165.7T DK1446093T3 (en) 2001-10-21 2002-10-18 POTENTIZED TOPICAL COMPOSITION
US10/491,992 US8642053B2 (en) 2001-10-21 2002-10-18 Potentiated topical composition
EP02778165.7A EP1446093B1 (fr) 2001-10-21 2002-10-18 Composition topique potentialisee
NZ533087A NZ533087A (en) 2001-10-21 2002-10-18 Potentiated topical composition comprising pentane-1,5-diol
CA2469474A CA2469474C (fr) 2001-10-21 2002-10-18 Composition topique potentialisee
AU2002339819A AU2002339819B2 (en) 2001-10-21 2002-10-18 Potentiated topical composition
ES02778165.7T ES2628707T3 (es) 2001-10-21 2002-10-18 Composición tópica potenciada

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0103528A SE0103528D0 (sv) 2001-10-21 2001-10-21 Topiska kompositioner med förstärkt effekt
SE0103528-6 2001-10-21

Publications (1)

Publication Number Publication Date
WO2003035021A1 true WO2003035021A1 (fr) 2003-05-01

Family

ID=20285740

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2002/001908 Ceased WO2003035021A1 (fr) 2001-10-21 2002-10-18 Composition topique potentialisee

Country Status (10)

Country Link
US (1) US8642053B2 (fr)
EP (1) EP1446093B1 (fr)
AU (1) AU2002339819B2 (fr)
CA (1) CA2469474C (fr)
DK (1) DK1446093T3 (fr)
ES (1) ES2628707T3 (fr)
NZ (1) NZ533087A (fr)
RU (1) RU2295956C2 (fr)
SE (1) SE0103528D0 (fr)
WO (1) WO2003035021A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006057616A1 (fr) * 2004-11-29 2006-06-01 Ambria Dermatology Ab Composition comprenant au moins 3 diols differents
SE533425C2 (sv) * 2008-07-07 2010-09-21 Ambria Dermatology Ab Antimikrobiell sammansättning
GB0912481D0 (en) * 2009-07-17 2009-08-26 Reckitt Benckiser Healthcare I Skincare compositions
RU2453305C1 (ru) * 2010-11-11 2012-06-20 Татьяна Владимировна Митрохина Лечебно-косметическое средство "белемнит" для лечения акне и псориаза
WO2016130931A2 (fr) * 2015-02-13 2016-08-18 The Johns Hopkins University Formulations de bloqueurs des récepteurs de l'angiotensine
JP6188855B1 (ja) * 2016-03-31 2017-08-30 大王製紙株式会社 ティシュペーパー
KR102331771B1 (ko) * 2017-09-28 2021-12-01 가부시키가이샤 만다무 반고체상 세정제
RU2742964C2 (ru) * 2019-03-18 2021-02-12 Юрий Александрович Захаров Косметическая композиция
RU2731807C1 (ru) * 2020-05-05 2020-09-08 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт ревматологии имени В.А.Насоновой» (ФГБНУ НИИР им. В.А. Насоновой) Способ определения показаний к началу приема генно-инженерных биологических препаратов при неэффективности базисных противовоспалительных препаратов при ранних формах псориатического артрита

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS572212A (en) * 1980-06-06 1982-01-07 Pola Chem Ind Inc Cosmetic
WO1993020812A1 (fr) * 1992-04-14 1993-10-28 Bioglan Ab Potentialisation d'effets antimicrobiens
EP1000542A1 (fr) * 1998-11-09 2000-05-17 L'oreal Système à activité antimicrobienne et son utilisation, notamment dans les domaines cosmétique et dermatologique
DE19857491A1 (de) * 1998-12-14 2000-06-15 Hans Lautenschlaeger Hautschutzpräparate zur Prävention von Hautschäden mit UV-Filtern
DE19857492A1 (de) * 1998-12-14 2000-06-15 Hans Lautenschlaeger Wasserhaltige Hautschutzpräparate zur Prävention von Hautschäden
EP1033127A1 (fr) * 1997-03-18 2000-09-06 Sunstar Inc. Composition con ue pour former des particules solides
WO2001007003A1 (fr) * 1999-07-22 2001-02-01 Unilever Plc Emulsions d'elastomere silicone stabilisees au pentylene glycol
EP1166762A1 (fr) * 2000-06-29 2002-01-02 JOHNSON & JOHNSON CONSUMER COMPANIES, INC. Compositions contenant de l'eau minérale

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3979463A (en) * 1970-10-27 1976-09-07 Minnesota Mining And Manufacturing Company Fluoroaliphatic phenols
US3996934A (en) * 1971-08-09 1976-12-14 Alza Corporation Medical bandage
JPS5729213B2 (fr) * 1974-11-12 1982-06-21
US4701320A (en) * 1984-11-29 1987-10-20 Lederle (Japan), Ltd. Composition stably containing minocycline for treating periodontal diseases
US4756906A (en) * 1986-03-18 1988-07-12 Minnesota Mining And Manufacturing Company Cosmetic colorant compositions
US5369129A (en) * 1989-06-13 1994-11-29 Hydro Pharma Ab Preparation of topical treatment of infections caused by virus, bacteria and fungi
US5641768A (en) * 1989-11-17 1997-06-24 Loria; Roger M. 5-androstene 3β, 17β diol for treatment
US5158978A (en) * 1990-02-05 1992-10-27 British Technology Group (U.S.A.) Thyroid hormone treatment of acute cardiovascular compromise
US5079003A (en) * 1990-03-14 1992-01-07 Adelia Scaffidi Skin lotions and creams
GB9010525D0 (en) * 1990-05-10 1990-07-04 Unilever Plc Cosmetic composition
DE4105345A1 (de) * 1991-02-21 1992-08-27 Kronos Int Inc Verfahren zur herstellung von feinteiligem titandioxid und feinteiliges titandioxid
JPH06510290A (ja) 1991-08-27 1994-11-17 シグナス，インコーポレイテッド プラゾシンを投与するための経皮処方物
JPH07501103A (ja) * 1991-11-12 1995-02-02 ネペラ　インコーポレイテッド 長い使用寿命をもつ接着性ヒドロゲルおよびその調製法
US5698589A (en) * 1993-06-01 1997-12-16 International Medical Innovations, Inc. Water-based topical cream containing nitroglycerin and method of preparation and use thereof
WO1995005137A1 (fr) 1993-08-16 1995-02-23 Cygnus Therapeutic Systems Systeme d'apport transcutane utilisant une combinaison de substances favorisant la penetration
EP0801941B1 (fr) * 1995-11-22 2003-08-06 Shiseido Company, Ltd. Produits cosmetiques
GR1002807B (el) * 1996-06-20 1997-11-13 Lavipharm A.E. Συστημα για την τοπικη θεραπεια της ακμης και μεθοδος παραγωγης του
US5728732A (en) * 1996-11-27 1998-03-17 Elizabeth Arden Company, Division Of Conopco, Inc. Skin treatment with salicylic acid esters and retinoids
GB9626513D0 (en) 1996-12-20 1997-02-05 Bioglan Ireland R & D Ltd A pharmaceutical composition
EP0966246A1 (fr) * 1997-08-28 1999-12-29 Wella Aktiengesellschaft Produit de soins cosmetiques a deux composantes
US6193996B1 (en) * 1998-04-02 2001-02-27 3M Innovative Properties Company Device for the transdermal delivery of diclofenac
CA2370633A1 (fr) * 1999-04-29 2000-11-09 Avon Products, Inc. Methode pour ameliorer l'aspect esthetique de l'epithelium
AU5460800A (en) * 1999-06-02 2000-12-18 Aviana Biopharm Pharmaceutical transdermal compositions
AU4552399A (en) 1999-06-10 2001-01-02 Alexander Galat Transdermally delivered aspirin
FR2794998B1 (fr) 1999-06-21 2001-07-27 Oreal Organogels et leurs utilisations notamment cosmetiques

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS572212A (en) * 1980-06-06 1982-01-07 Pola Chem Ind Inc Cosmetic
WO1993020812A1 (fr) * 1992-04-14 1993-10-28 Bioglan Ab Potentialisation d'effets antimicrobiens
EP1033127A1 (fr) * 1997-03-18 2000-09-06 Sunstar Inc. Composition con ue pour former des particules solides
EP1000542A1 (fr) * 1998-11-09 2000-05-17 L'oreal Système à activité antimicrobienne et son utilisation, notamment dans les domaines cosmétique et dermatologique
DE19857491A1 (de) * 1998-12-14 2000-06-15 Hans Lautenschlaeger Hautschutzpräparate zur Prävention von Hautschäden mit UV-Filtern
DE19857492A1 (de) * 1998-12-14 2000-06-15 Hans Lautenschlaeger Wasserhaltige Hautschutzpräparate zur Prävention von Hautschäden
WO2001007003A1 (fr) * 1999-07-22 2001-02-01 Unilever Plc Emulsions d'elastomere silicone stabilisees au pentylene glycol
EP1166762A1 (fr) * 2000-06-29 2002-01-02 JOHNSON & JOHNSON CONSUMER COMPANIES, INC. Compositions contenant de l'eau minérale

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 198207, Derwent World Patents Index; Class A96, AN 1982-12595SE, XP002960554 *

Also Published As

Publication number Publication date
AU2002339819B2 (en) 2007-03-15
ES2628707T3 (es) 2017-08-03
EP1446093A1 (fr) 2004-08-18
US20040248993A1 (en) 2004-12-09
US8642053B2 (en) 2014-02-04
DK1446093T3 (en) 2017-07-03
RU2295956C2 (ru) 2007-03-27
CA2469474A1 (fr) 2003-05-01
RU2004115747A (ru) 2005-04-10
EP1446093B1 (fr) 2017-03-22
CA2469474C (fr) 2014-04-15
NZ533087A (en) 2005-12-23
SE0103528D0 (sv) 2001-10-21

Similar Documents

Publication Publication Date Title
US7205003B2 (en) Method and topical formulation for treating skin conditions associated with aging
US4670185A (en) Aqueous vesicle dispersion having surface charge
ES2532133T3 (es) Composiciones y métodos para el tratamiento de enfermedades de la uña
US5639740A (en) Topical moisturizing composition and method
US5652256A (en) Topical composition for fungal treatment
CN103476396B (zh) 包含环状缩酚肽的混悬类型的局部制剂
AU2002339819B2 (en) Potentiated topical composition
AU2002339819A1 (en) Potentiated topical composition
JP3981074B2 (ja) オルニチンデカルボキシラーゼインヒビターの毛包輸送のための局所用組成物
US20110081387A1 (en) Liposomes encapsulating an oxazolidin-2-one compound
CA3085159C (fr) Compositions topiques comprenant des derives n-acyldipeptides et de l'acide glycolique
CA1294878C (fr) Composition pour la preparation improvisee de formulations pharmaceutiques et cosmetiques topiques
JP2001501609A (ja) 活性化合物の放出が高い抗真菌ゲル剤
WO2011061155A1 (fr) Formulations antifongiques et leur utilisation
US20100239655A1 (en) Taurine-based compositions and therapeutic methods
KR20240134863A (ko) 심부 진피 약물 전달을 위한 스피로노락톤의 약학 조성물
WO1998042348A1 (fr) Composition hydratante topique et methode associee
US4272516A (en) Process for improving transcutaneous and transfollicular absorption of cosmetic compositions
KR20050098583A (ko) 옥죽 파우더를 함유하는 피부보습용 화장료 조성물
CN119280100B (zh) 一种美白祛斑护肤用组合物、制备方法及护肤品
US20050255132A1 (en) Softening cream
Hänel et al. Formulation
Nazmi In-vitro release and antifungal activity of ketoconazole from different dermatological vehicles with reduced level of drug
US20040018220A1 (en) Aqueous compositions for facial cosmetics
Abd-ElGawad et al. Effect of Penetration Enhancers on the Permeability of Ketoconazole Gels Through Rabbit Skin

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REEP Request for entry into the european phase

Ref document number: 2002778165

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002778165

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002339819

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 302/MUMNP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 533087

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2469474

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 10491992

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2002778165

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 533087

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 533087

Country of ref document: NZ

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: JP

WWG Wipo information: grant in national office

Ref document number: 2002339819

Country of ref document: AU